Key result
Carvedilol treatment caused a 20% reduction in myocardial free fatty acid extraction and significantly reduced cardiac norepinephrine spillover compared to metoprolol in chronic heart failure.
Why the study?
Does carvedilol alter myocardial energy substrate utilization compared to metoprolol in patients with chronic heart failure?
Population
22 patients with chronic heart failure (CHF)
Comparison
Carvedilol for 4 months vs Metoprolol (selective beta-blocker) for 4 months
Design
RCT, randomised, double-blind
Follow-up
4 months
Authors
Loading...
Carvedilol may confer metabolic and sympatholytic benefits over metoprolol in heart failure; extends beta-blocker differentiation in RCTs.
RCT (n=22)
Double-blind
Randomized
Does carvedilol alter myocardial energy substrate utilization compared to metoprolol in patients with chronic heart failure?
p-value: p=<0.03
Carvedilol, but not metoprolol, reduces myocardial free fatty acid extraction and cardiac sympathetic activity in chronic heart failure, which may contribute to its favorable clinical effects.
Al‐Hesayen et al. (2004) conducted an RCT in Chronic heart failure (n=22). Carvedilol vs. Metoprolol was evaluated on Myocardial free fatty acid (FFA) uptake (p=<0.03). Carvedilol treatment caused a 20% reduction in myocardial free fatty acid extraction and significantly reduced cardiac norepinephrine spillover compared to metoprolol in chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: